Bimekizumab in the Treatment of Plaque Psoriasis: Focus on Patient Selection and Perspectives.

ABSTRACT: Psoriasis is a chronic systemic inflammatory disease that significatively impairs patients' quality of life. Biological treatments are highly effective and safe and have led to breakthroughs in the management of patients with moderate-to-severe psoriasis. However, therapeutic response can be unsatisfactory or lost with time, leading to discontinuation of treatment. Bimekizumab is a humanized monoclonal antibody that specifically inhibits both interleukin (IL)-17A and IL-17F. The efficacy and safety of bimekizumab in moderate-to-severe plaque psoriasis has been demonstrated in Phase 2 and Phase 3 clinical trials. Bimekizumab may offer some advantages over other biological treatments, making it especially indicated for certain patients. This narrative review aims to summarize the latest publ

SUBMITTER: Camina-Conforto G 

PROVIDER: S-EPMC10319282 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature